Testing a new drug for multiple sclerosis in healthy people and MS patients
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old (or 18-60 if you have MS).
- You are in good health with no major medical problems.
- You are willing to have a lumbar puncture (spinal tap) to collect fluid for testing.
- You can attend all study visits and follow the study rules.
- You do not have a history of drug abuse, heavy alcohol use, or smoking within the last week.
- You have not donated blood or plasma in the last month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called RO7121932 in people with multiple sclerosis. The goal is to see how safe it is and how the body processes it. It might help by offering a new way to manage the condition.
This study tests whether a medicine that targets a specific brain inflammation marker (TSPO) can help in people with certain types of multiple sclerosis. It focuses on safety and whether the target can be measured and influenced during treatment.
This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This Phase 1 study tests whether the antibiotic vancomycin can be given safely to people with newly diagnosed multiple sclerosis (or related early stages). It mainly focuses on safety and side effects, and whether the approach is feasible for this group.
This trial is looking at how people with multiple sclerosis experience clinical study enrollment and participation. It may help improve how future MS trials work and are explained, especially for different types of participants.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.